Durmaz, RKöroglu, MKüçükbay, HTemel, IÖzer, MKRefiq, MÇetinkaya, E2024-08-042024-08-0419980004-4172https://hdl.handle.net/11616/93682In previous studies many benzimidazole, imidazole and benzothiazole derivatives had been synthesized and their antimicrobial activities were tasted in vitro conditions. Four of these compounds showed minimal inhibitory concentrations (MIC) of 5-25 mu g/ml against standard strains and clinical isolates. In order to determine whether these four compounds can be used for therapeutic purpose, their serum MIC values and side effects on hepatic and renal functions were determined. Different concentrations of the compounds were tested on Wistar rats. Compound 1 was administered orally, intramuscularly and intravenously; compounds 2, 3 and 4 were given orally and intramuscularly. Blood samples were taken 4 and 24 h after administration of the compounds. Serum MIC Values were investigated by bioassay and serum levels of biochemical parameters by autoanalyzer. None of the tested compounds showed antimicrobial activity at their serum concentrations. Although creatinine activity was found at normal levels in all experiments, compounds 1 and 2 caused a significant increase in blood urea nitrogen (BUN) level. The values of aspartate aminotransferase and/or alanine aminotransferase and/or alkaline phosphatase which are characteristic for liver function were generally found at high levels. According to these results, it can be concluded that the tested compounds caused damage in liver and biliary tracts without antimicrobial activity by their serum concentrations.eninfo:eu-repo/semantics/closedAccessbenzimidazoles, antimicrobial activity, pharmacokineticsbenzothiazoles, antimicrobial activity, pharmacokineticsimidazoles, antimicrobial activity, pharmacokineticsArticle48121179118498939342-s2.0-0344628870N/AWOS:000077745600011Q3